Parvis Sadjadian

Hans Nolte Str. 1
Minden, NW 32429, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).

Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).

Journal: Cancers

Published: May 21, 2026

Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.

Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 01, 2025

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Journal: Leukemia

Published: August 13, 2024

Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.

Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.

Journal: European journal of haematology

Published: July 05, 2024

Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms.

Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms.

Journal: Hamostaseologie

Published: October 09, 2023

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET.

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET.

Journal: HemaSphere

Published: December 28, 2022

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.

Journal: Blood advances

Published: January 31, 2022

Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.

Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.

Journal: Leukemia

Published: November 17, 2021

A review of hydroxyurea-related cutaneous adverse events.

A review of hydroxyurea-related cutaneous adverse events.

Journal: Expert opinion on drug safety

Published: June 28, 2021

Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.

Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.

Journal: European journal of haematology

Published: June 10, 2021

Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].

Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 29, 2021

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.

Journal: Annals of hematology

Published: April 21, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026